Advertisement
Advertisement
RCUS
Arcus Biosciences, Inc.
24.74
USDSponsored
-0.12
-0.47%
May 12, 14:35 UTC -4
Open
RCUS Earnings Reports
Positive Surprise Ratio
RCUS beat 18 of 33 last estimates.
55%
Next Report
Date of Next Report
Aug 04, 2026
Estimate for Q2 26 (Revenue/ EPS)
$27.27M
/-$0.90
Implied change from Q1 26 (Revenue/ EPS)
+60.44%
/-11.76%
Implied change from Q2 25 (Revenue/ EPS)
-82.95%
/--
Arcus Biosciences, Inc. earnings per share and revenue
On May 05, 2026, RCUS reported earnings of -1.02 USD per share (EPS) for Q1 26, missing the estimate of -0.89 USD, resulting in a -14.04% surprise. Revenue reached 17.00 million, compared to an expected 30.07 million, with a -43.47% difference. The market reacted with a -0.23% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of -0.90 USD, with revenue projected to reach 27.27 million USD, implying an decrease of -11.76% EPS, and increase of 60.44% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Halozyme Therapeutics, Inc.
Report Date
May 11, 2026 For Q1 26
Estimate
$1.56
Actual
$1.60
Surprise
+2.52%
Legend Biotech Corporation - ADR
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.15
Surprise
-597.67%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.53
Actual
-$0.52
Surprise
+3.60%
Bicara Therapeutics Inc. Common Stock
Report Date
May 11, 2026 For Q1 26
Estimate
-$0.66
Actual
-$0.93
Surprise
-39.98%
Arvinas, Inc
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.93
Actual
-$0.90
Surprise
+4.00%
LENZ Therapeutics, Inc. Common Stock
Report Date
May 11, 2026 For Q1 26
Estimate
-$1.09
Actual
-$1.32
Surprise
-21.05%
Tenax Therapeutics, Inc.
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.40
Actual
-$0.35
Surprise
+14.22%
SAB Biotherapeutics, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.23
Actual
-$0.35
Surprise
-50.28%
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.41
Actual
-$0.33
Surprise
+19.67%
Imunon, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$1.13
Actual
-$0.84
Surprise
+25.81%
FAQ
What were Arcus Biosciences, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Arcus Biosciences, Inc. reported EPS of -$1.02, missing estimates by -14.04%, and revenue of $17.00M, -43.47% below expectations.
How did the market react to Arcus Biosciences, Inc.'s Q1 2026 earnings?
The stock price moved down -0.23%, changed from $26.06 before the earnings release to $26.00 the day after.
When is Arcus Biosciences, Inc. expected to report next?
The next earning report is scheduled for Aug 04, 2026.
What are the forecasts for Arcus Biosciences, Inc.'s next earnings report?
Based on 7
analysts, Arcus Biosciences, Inc. is expected to report EPS of -$0.90 and revenue of $27.27M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement